JP2018502087A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502087A5 JP2018502087A5 JP2017533810A JP2017533810A JP2018502087A5 JP 2018502087 A5 JP2018502087 A5 JP 2018502087A5 JP 2017533810 A JP2017533810 A JP 2017533810A JP 2017533810 A JP2017533810 A JP 2017533810A JP 2018502087 A5 JP2018502087 A5 JP 2018502087A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- acceptable salt
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 201000011510 cancer Diseases 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 19
- 229940123237 Taxane Drugs 0.000 claims description 15
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 15
- 230000035772 mutation Effects 0.000 claims description 10
- 229940126062 Compound A Drugs 0.000 claims description 9
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 9
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical group N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims description 7
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims description 7
- 229930012538 Paclitaxel Natural products 0.000 claims description 7
- 229960001592 paclitaxel Drugs 0.000 claims description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 101710113436 GTPase KRas Proteins 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 229940028652 abraxane Drugs 0.000 claims description 2
- 201000009036 biliary tract cancer Diseases 0.000 claims description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000001926 lymphatic effect Effects 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 claims description 2
- 201000008106 ocular cancer Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 229940123690 Raf kinase inhibitor Drugs 0.000 description 9
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 description 9
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- VWMJHAFYPMOMGF-UHFFFAOYSA-N CC(c1ncc(C(Nc(cc2C(F)(F)F)ncc2Cl)=O)[s]1)NC(c1ncnc(N)c1Cl)=O Chemical compound CC(c1ncc(C(Nc(cc2C(F)(F)F)ncc2Cl)=O)[s]1)NC(c1ncnc(N)c1Cl)=O VWMJHAFYPMOMGF-UHFFFAOYSA-N 0.000 description 1
- OYXSNFKGKQSWRJ-UHFFFAOYSA-N CC(c1ncc(C(Nc(nc2)cc(C(F)(F)F)c2Cl)=O)[s]1)NC(c1ncnc(NC)c1Cl)=O Chemical compound CC(c1ncc(C(Nc(nc2)cc(C(F)(F)F)c2Cl)=O)[s]1)NC(c1ncnc(NC)c1Cl)=O OYXSNFKGKQSWRJ-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096020P | 2014-12-23 | 2014-12-23 | |
| US62/096,020 | 2014-12-23 | ||
| US201562242629P | 2015-10-16 | 2015-10-16 | |
| US62/242,629 | 2015-10-16 | ||
| PCT/US2015/067462 WO2016106359A1 (en) | 2014-12-23 | 2015-12-22 | Combination of raf inhibitors and taxanes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020065763A Division JP2020114857A (ja) | 2014-12-23 | 2020-04-01 | Ｒａｆ阻害剤及びタキサンの組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018502087A JP2018502087A (ja) | 2018-01-25 |
| JP2018502087A5 true JP2018502087A5 (enExample) | 2019-02-07 |
Family
ID=56151531
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533810A Pending JP2018502087A (ja) | 2014-12-23 | 2015-12-22 | Ｒａｆ阻害剤及びタキサンの組み合わせ |
| JP2020065763A Pending JP2020114857A (ja) | 2014-12-23 | 2020-04-01 | Ｒａｆ阻害剤及びタキサンの組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020065763A Pending JP2020114857A (ja) | 2014-12-23 | 2020-04-01 | Ｒａｆ阻害剤及びタキサンの組み合わせ |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20190117652A1 (enExample) |
| EP (1) | EP3236966B1 (enExample) |
| JP (2) | JP2018502087A (enExample) |
| CN (1) | CN107405348B (enExample) |
| CA (1) | CA2972189A1 (enExample) |
| ES (1) | ES2827024T3 (enExample) |
| WO (1) | WO2016106359A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4065122A4 (en) * | 2019-11-27 | 2023-12-27 | Day One Biopharmaceuticals, Inc. | Solid dispersion of pan-raf kinase inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008001933A1 (es) * | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| CA2694646C (en) * | 2007-07-30 | 2017-09-05 | Ardea Biosciences, Inc. | Combinations of mek inhibitors and raf kinase inhibitors and uses thereof |
| JO3101B1 (ar) * | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| KR20110100241A (ko) * | 2008-12-05 | 2011-09-09 | 아르퀼 인코포레이티드 | Ｒａｆ 억제제 및 이들의 용도 |
| RU2553379C2 (ru) * | 2009-08-24 | 2015-06-10 | Дженентек, Инк. | ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ K-ras И УРОВНЕЙ ЭКСПРЕССИИ RTK |
| WO2013144923A1 (en) * | 2012-03-30 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma |
| CA2904338C (en) * | 2013-03-05 | 2022-07-05 | University Of Tennessee Research Foundation | Use of imidazole derivatives in combination with a braf inhibitor or mek inhibitor in the treatment of cancer |
| UY36046A (es) * | 2014-03-26 | 2015-10-30 | Millennium Pharm Inc | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso |
-
2015
- 2015-12-22 ES ES15874331T patent/ES2827024T3/es active Active
- 2015-12-22 CN CN201580073526.5A patent/CN107405348B/zh active Active
- 2015-12-22 JP JP2017533810A patent/JP2018502087A/ja active Pending
- 2015-12-22 WO PCT/US2015/067462 patent/WO2016106359A1/en not_active Ceased
- 2015-12-22 CA CA2972189A patent/CA2972189A1/en not_active Abandoned
- 2015-12-22 US US15/539,185 patent/US20190117652A1/en not_active Abandoned
- 2015-12-22 EP EP15874331.0A patent/EP3236966B1/en active Active
-
2020
- 2020-04-01 JP JP2020065763A patent/JP2020114857A/ja active Pending
- 2020-06-01 US US16/889,408 patent/US20200316067A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102490334B1 (ko) | 암 치료용 아젤니디핀 약학 조성물의 새로운 적응증 | |
| MX2019013701A (es) | Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos. | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| JP2015512398A5 (enExample) | ||
| JP2016528301A5 (enExample) | ||
| JP2011079858A5 (enExample) | ||
| RU2016112608A (ru) | Лечение рака комбинацией плинабулина и таксана | |
| EA201171088A1 (ru) | Лечение дискинезии при различных расстройствах | |
| JP2016529285A5 (enExample) | ||
| JP2016517888A5 (enExample) | ||
| JP2016525097A5 (enExample) | ||
| JP2019532047A5 (enExample) | ||
| EA200802350A2 (ru) | Система доставки лекарств | |
| JP2017524003A5 (enExample) | ||
| EA201590847A1 (ru) | Новые ингибиторы rock | |
| JP2017533220A5 (enExample) | ||
| JP2019530706A5 (enExample) | ||
| JP2017526695A5 (enExample) | ||
| JP2020537695A (ja) | ストレプトニグリンおよびラパマイシンを有効成分として含む、癌の予防または治療用薬学的組成物 | |
| MX2022011372A (es) | Composiciones de zinc-y-pga y metodos para tratar el cancer. | |
| EA201591188A1 (ru) | Доставка глатирамера ацетата через слизистую оболочку | |
| JP2014148552A5 (enExample) | ||
| JP2019507786A5 (enExample) | ||
| WO2014075203A1 (es) | Nanopartículas con polímero biodegradable y biocompatible plga cargadas con el fármaco de uso humano pentoxfilina | |
| JP2018502087A5 (enExample) |